+

WO2018169053A1 - Cathéter à ballonnet, son procédé de production, dispositif de production, et procédé de traitement - Google Patents

Cathéter à ballonnet, son procédé de production, dispositif de production, et procédé de traitement Download PDF

Info

Publication number
WO2018169053A1
WO2018169053A1 PCT/JP2018/010472 JP2018010472W WO2018169053A1 WO 2018169053 A1 WO2018169053 A1 WO 2018169053A1 JP 2018010472 W JP2018010472 W JP 2018010472W WO 2018169053 A1 WO2018169053 A1 WO 2018169053A1
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
metal layer
drug
solvent
catheter
Prior art date
Application number
PCT/JP2018/010472
Other languages
English (en)
Japanese (ja)
Inventor
村田悠
黒崎靖夫
後藤博
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Priority to JP2019506299A priority Critical patent/JP7073338B2/ja
Publication of WO2018169053A1 publication Critical patent/WO2018169053A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/10—Inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters

Definitions

  • the present invention relates to a balloon catheter in which a drug is provided on the outer surface of the balloon, a method and apparatus for manufacturing the balloon catheter, and a treatment method.
  • the balloon catheter has been used to improve a lesion (stenosis) occurring in a living body lumen.
  • the balloon catheter usually includes a long shaft portion and a balloon that is provided on the distal end side of the shaft portion and is expandable in the radial direction. By expanding the deflated balloon after reaching a target location in the body via a thin living body lumen, the lesioned part can be expanded.
  • a drug eluting balloon in which a drug for suppressing stenosis is coated on the outer surface of the balloon is used.
  • the drug coated on the outer surface is instantaneously released to the lesioned part, thereby preventing restenosis.
  • the morphological form of the drug coated on the outer surface of the balloon affects the drug release from the balloon surface and the tissue transferability at the lesion.
  • the form of the drug coated on the outer surface of the balloon can be adjusted by changing the conditions for volatilizing the solvent after applying a coating liquid containing the drug and the solvent to the outer surface of the balloon.
  • Patent Document 1 describes a method of drying a coating composition applied to a balloon while applying a fluid for adjusting the temperature condition of the coating composition inside the balloon.
  • Patent Document 2 describes a method in which conductive ink is applied to a balloon by a method such as pad printing, ink jet printing, spraying, marker striping, painting, or electrostatic coating. Thereby, it becomes possible to flow an electric current through the stent mounted on the balloon, and it is possible to apply a coating to the stent by an electrostatic coating method.
  • JP 2014-200269 A International Publication No. 2005/060870
  • Patent Document 1 The method described in Patent Document 1 is complicated because it requires a fluid whose temperature is controlled to flow into a rotating balloon.
  • the method described in Patent Document 2 is a technique for applying a coating of a drug or the like to a stent by electrostatic coating, and does not increase the uniformity of the drug provided on the balloon.
  • the present invention has been made to solve the above-described problem, and a balloon catheter capable of uniformly forming a drug crystal on the outer surface of the balloon and easily controlling the morphological type of the drug, and a manufacturing method and a manufacturing apparatus thereof.
  • An object of the present invention is to provide a treatment method.
  • a method for manufacturing a balloon catheter that achieves the above object is a method for manufacturing a balloon catheter in which a coating layer containing a water-insoluble drug crystal is formed on the outer surface of the balloon, and a conductive metal is applied to the outer surface of the balloon.
  • a current is passed through the metal layer to generate heat to volatilize the solvent.
  • the balloon catheter manufacturing method configured as described above was applied because the coating solution solvent can be volatilized by heating with a metal layer in a state where the coating solution solvent remains in the entire range applied. Crystallization of the entire range of drugs can be promoted simultaneously under substantially the same conditions. For this reason, drug crystals can be uniformly formed on the outer surface of the balloon, and the morphological form of the drug can be easily controlled regardless of various conditions and fluctuations in the procedure.
  • a current is supplied to the metal layer by a terminal that is slidably in contact with the metal layer while rotating the balloon around the axis of the balloon. Good. Thereby, an electric current can be sent through a metal layer and a solvent can be volatilized, without stopping rotation of the balloon which plays the role which makes a coating liquid uniform. For this reason, drug crystals can be formed uniformly, and the morphological type of the drug can be easily controlled.
  • the solvent is water, acetic acid, benzene, chlorohexane, glycerin, ethanol, hexane, ethyl acetate, o-dichlorobenzene, o-xylene, p-xylene, cyclohexanol, styrene, cyclohexane, i-butyl alcohol, s-butyl. It may be at least one selected from the group consisting of alcohol, t-butyl alcohol, propanol, butanol, toluene, and ethylene glycol. Thereby, the volatility of the solvent is lowered, and the solvent is less likely to volatilize from the coating liquid applied to the balloon.
  • the water-insoluble drug may be rapamycin, paclitaxel, docetaxel, or everolimus.
  • An apparatus for manufacturing a balloon catheter that achieves the above object applies a rotating mechanism that applies a rotational force to the balloon, and a coating solution containing a drug and a solvent on the outer surface of a metal layer deposited on the rotating balloon.
  • a supply unit and a terminal that slidably contacts the metal layer and supplies current to the metal layer.
  • the balloon catheter manufacturing apparatus configured as described above has a current flowing in the metal layer by means of a terminal that slidably contacts the metal layer of the rotating balloon with the solvent of the coating solution remaining in the entire range. To heat the metal layer and volatilize the solvent of the coating solution. For this reason, crystallization of the whole range of the applied drug can be promoted simultaneously under substantially the same conditions. Therefore, drug crystals can be uniformly formed on the outer surface of the balloon, and the morphological type of the drug can be easily controlled, regardless of various conditions and fluctuations in the procedure.
  • a balloon catheter that achieves the above-mentioned object is a balloon catheter that can be inserted into a living body lumen, and is a long catheter body, a balloon that is provided on the distal side of the catheter body and is expandable in the radial direction, A metal layer deposited on the outer surface of the balloon; a water-insoluble drug crystal disposed on the outer surface of the metal layer; and a proximal side along the catheter body electrically connected to the metal layer And a conductive wire extending to the surface.
  • the balloon catheter configured as described above can supply an electric current to the metal layer disposed on the balloon inserted into the living body via a lead wire. For this reason, the drug crystal can be heated in the living body to improve the transferability of the drug to the living tissue.
  • a treatment method for achieving the above object is a treatment method for delivering a drug to a lesion in a living body lumen using a balloon catheter, the step of inserting the balloon into the living body lumen to reach the lesion Expanding the balloon and the metal layer to press against the living tissue, and bringing the drug crystal into contact with the living tissue; passing an electric current through the conductor to the metal layer to heat the metal layer; Heating the drug crystal; and deflating the balloon to remove it from the living body lumen.
  • the treatment method configured as described above generates heat in the metal layer and heats the drug crystal, it is possible to improve the transferability of the drug to a living tissue.
  • the balloon catheter 10 is a drug-eluting catheter in which drug crystals are provided on the outer surface of the balloon 30 as shown in FIGS.
  • the side of the balloon catheter 10 to be inserted into the living body lumen is referred to as “tip” or “tip side”
  • the proximal side for operation is referred to as “base end” or “base end side”.
  • the balloon catheter 10 includes a long catheter body 20, a balloon 30 provided at the distal end of the catheter body 20, a metal layer 37 provided on the outer surface of the balloon 30, and a drug provided on the outer surface of the metal layer 37.
  • the coating layer 40 includes a hub 26 fixed to the proximal end of the catheter body 20.
  • the catheter body 20 includes an outer tube 21 that is a tube having an open front end and a proximal end, and an inner tube 22 that is a tube disposed inside the outer tube 21.
  • the inner tube 22 is housed in the hollow interior of the outer tube 21, and the catheter body 20 has a double tube structure at the distal end.
  • the hollow interior of the inner tube 22 is a guide wire lumen 24 through which the guide wire is inserted.
  • an expansion lumen 23 through which the expansion fluid of the balloon 30 flows is formed inside the hollow of the outer tube 21 and outside the inner tube 22.
  • the inner tube 22 opens to the outside at the opening 25.
  • the inner tube 22 protrudes further to the distal end side than the distal end of the outer tube 21.
  • the balloon 30 has a proximal end portion fixed to the distal end portion of the outer tube 21 and a distal end portion fixed to the distal end portion of the inner tube 22. Thereby, the inside of the balloon 30 communicates with the expansion lumen 23.
  • the balloon 30 can be expanded by injecting an expansion fluid into the balloon 30 through the expansion lumen 23.
  • the expansion fluid may be a gas or a liquid.
  • a gas such as helium gas, CO 2 gas, O 2 gas, N 2 gas, Ar gas, air, mixed gas, or a liquid such as physiological saline or contrast medium is used. Can do.
  • a cylindrical straight portion 31 having the same outer diameter when expanded is formed in the central portion of the balloon 30 in the axial direction, and a taper whose outer diameter gradually changes on both sides of the straight portion 31 in the axial direction.
  • a portion 33 is formed.
  • medical agent is formed in the whole outer surface of the straight part 31.
  • FIG. The range in which the coating layer 40 is formed in the balloon 30 is not limited to the straight portion 31, and may include at least a part of the tapered portion 33 in addition to the straight portion 31, or one of the straight portions 31. It may be only part.
  • the hub 26 is formed with a base end opening portion 27 that functions as a port that communicates with the expansion lumen 23 of the outer tube 21 and allows the expansion fluid to flow in and out.
  • the length of the balloon 30 in the axial direction is not particularly limited, but is preferably 5 to 500 mm, more preferably 10 to 300 mm, and still more preferably 20 to 200 mm.
  • the outer diameter of the balloon 30 at the time of expansion is not particularly limited, but is preferably 1 to 10 mm, more preferably 2 to 8 mm.
  • the outer surface of the balloon 30 before the metal layer 37 and the coat layer 40 are formed is smooth and non-porous.
  • the outer surface of the balloon 30 before the metal layer 37 and the coat layer 40 are formed may have minute holes that do not penetrate the membrane.
  • the outer surface of the balloon 30 before the coating layer 40 is formed may have both a smooth and non-porous range and a range with minute holes that do not penetrate the membrane.
  • the size of the minute holes is, for example, 0.1 to 5 ⁇ m in diameter and 0.1 to 10 ⁇ m in depth, and may have one or a plurality of holes for one crystal.
  • the size of the minute holes is, for example, a diameter of 5 to 500 ⁇ m and a depth of 0.1 to 50 ⁇ m, and one hole or a plurality of crystals may be included for one hole.
  • the balloon 30 has a certain degree of flexibility so that it can be expanded when it reaches a blood vessel, tissue, etc., and has a certain degree of hardness so that the drug can be released from the coat layer 40 on its outer surface.
  • the balloon 30 is made of metal or resin, but at least the outer surface of the balloon 30 on which the coat layer 40 is provided is preferably made of resin.
  • the constituent material of at least the outer surface of the balloon 30 is, for example, a polyolefin such as polyethylene, polypropylene, polybutene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, ionomer, or a mixture of two or more of these, soft poly
  • a thermoplastic resin such as vinyl chloride resin, polyamide, polyamide elastomer, nylon elastomer, polyester, polyester elastomer, polyurethane, fluororesin, silicone rubber, latex rubber, or the like can be used.
  • polyamides are preferable. That is, at least a part of the outer surface of the balloon 30 that coats the drug is a polyamide.
  • the polyamide is not particularly limited as long as it is a polymer having an amide bond.
  • polytetramethylene adipamide nylon 46
  • polycaprolactam nylon 6
  • polyhexamethylene adipamide nylon 66
  • Homopolymers such as polyhexamethylene sebacamide (nylon 610), polyhexamethylene dodecamide (nylon 612), polyundecanolactam (nylon 11), polydodecanolactam (nylon 12), caprolactam / lauryl lactam copolymer Polymer (nylon 6/12), caprolactam / aminoundecanoic acid copolymer (nylon 6/11), caprolactam / ⁇ -aminononanoic acid copolymer (nylon 6/9), caprolactam / hexamethylene diammonium adipate copolymer ( Nylon 6/66 Copolymers such as a copolymer of adipic acid and meta-x
  • a polyamide elastomer which is a block copolymer having nylon 6, nylon 66, nylon 11, nylon 12 or the like as a hard segment and polyalkylene glycol, polyether, aliphatic polyester or the like as a soft segment is also a material of the balloon 30.
  • the said polyamides may be used individually by 1 type, and may use 2 or more types together.
  • the balloon 30 preferably has a smooth surface of polyamide.
  • a conductive metal material is deposited on the outer surface of the balloon 30 to form a metal layer 37, and a coat layer 40 is formed on the outer surface.
  • the constituent material of the metal layer 37 is a conductive metal, for example, gold (Au), platinum (Pt), chromium (Cr), zinc (Zn), nickel (Ni), silver (Ag), copper (Cu ) And alloys thereof.
  • the thickness of the metal layer 37 is not particularly limited as long as it can be formed to have conductivity by vapor deposition and does not hinder the flexibility of the balloon 30, but is, for example, 0.1 to 500 nm, preferably 0.1 It is ⁇ 100 nm, more preferably 0.1 to 50 nm.
  • the coat layer 40 includes an additive 41 (excipient) containing a water-soluble low-molecular compound disposed in a layered manner on the outer surface of the metal layer 37 of the balloon 30, and a water-insoluble extending with an independent long axis.
  • the drug crystal 42 is included.
  • the end of the drug crystal 42 may be in direct contact with the outer surface of the metal layer 37, but the additive 41 is not directly contacted between the end of the drug crystal 42 and the outer surface of the metal layer 37. May be present.
  • the end portion of the drug crystal 42 may be positioned on the surface of the layer of the additive 41, and the drug crystal 42 may protrude from the additive 41.
  • the plurality of drug crystals 42 may be regularly arranged on the outer surface of the metal layer 37. Alternatively, the plurality of drug crystals 42 may be irregularly arranged on the outer surface of the metal layer 37.
  • the amount of the drug contained in the coat layer 40 is not particularly limited, but is 0.1 ⁇ g / mm 2 to 10 ⁇ g / mm 2 , preferably 0.5 ⁇ g / mm 2 to 5 ⁇ g / mm 2 , more preferably 0.5 ⁇ g. / Mm 2 to 3.5 ⁇ g / mm 2 , more preferably 1.0 ⁇ g / mm 2 to 3 ⁇ g / mm 2 .
  • the amount of crystals of the coat layer 40 is not particularly limited, but is preferably 5 to 500,000 [crystal / (10 ⁇ m 2 )] (number of crystals per 10 ⁇ m 2 ), more preferably 50 to 50,000 [crystal / (10 ⁇ m 2 )], more preferably 500 to 5,000 [crystal / (10 ⁇ m 2 )].
  • the drug crystal 42 may have a form having independent long axes. Further, the drug crystal 42 may be other morphological types.
  • the plurality of drug crystals 42 may be present in a state where they are combined, or may be present in contact with each other with a plurality of adjacent drug crystals 42 forming different angles.
  • the plurality of drug crystals 42 may be positioned on the surface of the metal layer 37 with a space (a space not including a crystal). On the surface of the metal layer 37, there may be both a plurality of drug crystals 42 in a combined state and a plurality of drug crystals 42 that are separated from each other and independent.
  • the plurality of drug crystals 42 may be arranged in a brush shape around the circumference having different major axis directions.
  • Each of the drug crystals 42 exists independently, has a certain length, and one end (base end) of the length portion is fixed to the additive 41 or the metal layer 37.
  • the drug crystal 42 does not form a complex structure with the adjacent drug crystal 42 and is not connected.
  • the major axis of the crystal is almost linear.
  • the drug crystal 42 forms a predetermined angle with respect to the surface with which the base portion where the major axes intersect is in contact.
  • the drug crystals 42 stand independently without contacting each other.
  • the base of the drug crystal 42 may be in contact with another base on the metal layer 37.
  • the base of the drug crystal 42 may be independent on the metal layer 37 without being in contact with other bases.
  • the drug crystal 42 may be hollow or solid. Both the hollow drug crystal 42 and the solid drug crystal 42 may exist on the surface of the metal layer 37. When the drug crystal 42 is hollow, at least the vicinity of its tip is hollow.
  • the cross section of the drug crystal 42 in a plane perpendicular to the major axis of the drug crystal 42 (perpendicular) has a hollow.
  • the drug crystal 42 having the hollow has a polygonal cross section of the drug crystal 42 in a plane perpendicular (perpendicular) to the long axis.
  • the polygon is, for example, a triangle, a tetragon, a pentagon, or a hexagon.
  • the drug crystal 42 has a distal end (or distal end surface) and a proximal end (or proximal end surface), and a side surface between the distal end (or distal end surface) and the proximal end (or proximal end surface) is a plurality of substantially flat surfaces. It is formed as a configured long polyhedron.
  • This crystal form type (hollow elongated body crystal form type) constitutes the whole or at least a part of a certain plane on the surface in contact with the base.
  • the length in the major axis direction of the drug crystal 42 having a major axis is preferably 5 ⁇ m to 20 ⁇ m, more preferably 9 ⁇ m to 11 ⁇ m, and even more preferably around 10 ⁇ m.
  • the diameter of the drug crystal 42 having a long axis is preferably 0.01 ⁇ m to 5 ⁇ m, more preferably 0.05 ⁇ m to 4 ⁇ m, and even more preferably 0.1 ⁇ m to 3 ⁇ m.
  • a combination having a diameter of 0.01 to 5 ⁇ m when the length is 5 ⁇ m to 20 ⁇ m, and a combination when the length is 5 to 20 ⁇ m examples include combinations having a diameter of 0.05 to 4 ⁇ m, and combinations having a diameter of 0.1 to 3 ⁇ m when the length is 5 to 20 ⁇ m.
  • the drug crystal 42 having the long axis is linear in the long axis direction, but may be curved. Both the linear drug crystal 42 and the curved drug crystal 42 may exist on the surface of the metal layer 37.
  • the above-mentioned crystal form type having a crystal having a long axis is 50% by volume or more, and more preferably 70% by volume or more with respect to the entire drug crystal on the outer surface of the metal layer 37.
  • the drug crystal 42 which is a crystal particle having a long axis, is formed so as to stand on the outer surface of the metal layer 37 or the additive 41.
  • the additive 41 is present in the region where the drug crystal 42 is present, and may not be present in the region where the drug crystal 42 is absent.
  • the additive 41 is distributed and present in the space between the plurality of drug crystals 42 in the forest.
  • the proportion of the substance constituting the coat layer 40 is preferably such that the water-insoluble drug crystal 42 occupies a larger volume than the additive 41.
  • the additive 41 does not form a matrix.
  • the matrix is a layer in which a relatively high-molecular substance (polymer or the like) is continuously formed, forms a network-like three-dimensional structure, and has a fine space therein. Therefore, the water-insoluble drug constituting the crystal is not attached to the matrix material.
  • the water-insoluble drug constituting the crystal is not embedded in the matrix material.
  • the additive 41 may form a matrix.
  • the additive 41 is coated on the outer surface of the metal layer 37 while being dissolved in a solvent, and then dried to form a layer.
  • the additive 41 is amorphous.
  • the additive 41 may be crystal particles.
  • Additive 41 may be present as a mixture of amorphous and crystalline particles.
  • the additive 41 in FIG. 3 is in the state of crystal grains and / or particulate amorphous. Alternatively, the additive 41 may be in a film-like amorphous state.
  • the additive 41 is formed as a layer containing a water-insoluble drug. Alternatively, the additive 41 may be formed as an independent layer that does not contain a water-insoluble drug.
  • the thickness of the additive 41 is 0.1 to 5 ⁇ m, preferably 0.3 to 3 ⁇ m, more preferably 0.5 to 2 ⁇ m.
  • the layer containing the drug crystal 42 of a long crystal form type has low toxicity and high stenosis-inhibiting effect when delivered into the body.
  • a water-insoluble drug containing a hollow long crystalline form is effective because it has good permeability to the tissue and good solubility because one unit of the crystal becomes small when the drug moves into the tissue. It can act to suppress stenosis.
  • toxicity is low because the drug hardly remains in the tissue as a large mass.
  • the layer containing the drug crystal 42 having a long crystal form type has a small crystal size (length in the long axis direction) that moves to the tissue of about 10 ⁇ m. Therefore, it acts uniformly on the affected part of the lesion and increases tissue permeability. Furthermore, since the size of the transferred drug crystal 42 is small, an excessive amount of drug does not stay in the affected area for an excessive period of time, so that it is possible to exhibit a high stenosis suppressing effect without developing toxicity. Think.
  • the drug coated on the outer surface of the metal layer 37 may include an amorphous type.
  • the drug crystal 42 and the amorphous may be arranged so as to have regularity in the coat layer 40. Alternatively, crystals and amorphous materials may be arranged irregularly.
  • the manufacturing apparatus 50 can form the metal layer 37 and the coat layer 40 on the balloon 30.
  • the balloon catheter manufacturing apparatus 50 includes a rotation mechanism 60 that rotates the balloon catheter 10 and a support base 70 that supports the balloon catheter 10.
  • the manufacturing apparatus 50 further includes a coating liquid supply unit 90 provided with a dispensing tube 94 that applies the coating liquid 45 to the outer surface of the metal layer 37, and a moving mechanism unit 80 that moves the dispensing tube 94 relative to the balloon 30. And have.
  • the manufacturing apparatus 50 further includes a current supply unit 110 that supplies current to the metal layer 37, a vapor deposition apparatus 120 that deposits metal on the outer surface of the balloon 30 to form the metal layer 37, and each part of the manufacturing apparatus 50. And a control unit 100 for controlling.
  • the rotation mechanism unit 60 holds the hub 26 of the balloon catheter 10 and rotates the balloon catheter 10 about the axis of the balloon 30 by a built-in driving source such as a motor.
  • a built-in driving source such as a motor.
  • the core material 61 is inserted and held in the guide wire lumen 24, and the core material 61 prevents the coating liquid 45 from flowing into the guide wire lumen 24.
  • a three-way cock that can open and close the flow path is connected to the proximal end opening 27 of the hub 26 in order to control the flow of fluid to the expansion lumen 23.
  • the support base 70 includes a tubular proximal end support portion 71 that accommodates the catheter main body 20 in a rotatable manner, and a distal end side support portion 72 that rotatably supports the core member 61. Note that the distal end side support portion 72 may rotatably support the distal end portion of the catheter body 20 instead of the core member 61 if possible.
  • the moving mechanism unit 80 includes a moving table 81 that can move linearly in a direction parallel to the axis of the balloon 30 and a tube fixing unit 83 to which the dispensing tube 94 is fixed.
  • the moving table 81 can move linearly by a driving source such as a built-in motor. As the moving table 81 moves, the dispensing tube 94 linearly moves in a direction parallel to the axis of the balloon 30.
  • the moving table 81 has a coating liquid supply unit 90 mounted thereon, and linearly moves the coating liquid supply unit 90 in both directions along the axis.
  • the coating liquid supply unit 90 is a part that applies the coating liquid 45 to the metal layer 37 on the surface of the balloon 30.
  • the coating liquid supply unit 90 includes a container 92 that stores the coating liquid 45, a liquid feeding pump 93 that feeds the coating liquid 45 in an arbitrary liquid feeding amount, and a dispensing tube 94 that applies the coating liquid 45 to the metal layer 37. And.
  • the liquid feed pump 93 is, for example, a syringe pump, and is controlled by the control unit 100 to suck the coating liquid 45 from the container 92 through the suction tube 91 and to the dispensing tube 94 through the supply tube 96. Can be supplied at an arbitrary liquid feeding amount.
  • the liquid feed pump 93 is installed on the moving table 81 and can move linearly by the movement of the moving table 81.
  • the liquid feed pump 93 is not limited to a syringe pump as long as the coating liquid 45 can be fed, and may be a tube pump, for example.
  • the dispensing tube 94 communicates with the supply tube 96 and discharges the coating liquid 45 supplied from the liquid feed pump 93 through the supply tube 96 to the metal layer 37 on the surface of the balloon 30.
  • the dispensing tube 94 is a flexible tubular member.
  • the dispensing tube 94 has an upper end fixed to the tube fixing portion 83, extends vertically downward from the tube fixing portion 83, and has an opening 95 at the discharge end 97 that is the lower end.
  • the dispensing tube 94 can move linearly in both directions along the axial direction of the balloon catheter 10 together with the liquid feed pump 93 installed on the moving table 81 by moving the moving table 81.
  • the dispensing tube 94 can supply the coating liquid 45 to the metal layer 37 in a state where the dispensing tube 94 is pressed against the metal layer 37 and is bent.
  • the dispensing tube 94 may not be a circular tube as long as the coating liquid 45 can be supplied.
  • the dispensing tube 94 may not extend in the vertical direction as long as the coating liquid 45 can be discharged from the opening 95.
  • the dispensing tube 94 may supply the coating liquid 45 to the metal layer 37 at a position away from the outer surface of the metal layer 37.
  • the dispensing tube 94 is preferably made of a flexible material so as to reduce the contact load on the metal layer 37 and absorb the change in the contact position accompanying the rotation of the balloon 30 by bending.
  • the constituent material of the dispensing tube 94 is, for example, polyolefin such as polyethylene and polypropylene, cyclic polyolefin, polyester, polyamide, polyurethane, PTFE (polytetrafluoroethylene), ETFE (tetrafluoroethylene / ethylene copolymer), PFA (tetra Fluororesin such as fluoroethylene / perfluoroalkyl vinyl ether copolymer) or FEP (tetrafluoroethylene / hexafluoropropylene copolymer) can be applied, but if it is flexible and deformable There is no particular limitation.
  • the outer diameter of the dispensing tube 94 is not particularly limited, but is, for example, 0.1 mm to 5.0 mm, preferably 0.15 mm to 3.0 mm, and more preferably 0.3 mm to 2.5 mm.
  • the inner diameter of the dispensing tube 94 is not particularly limited, but is, for example, 0.05 mm to 3.0 mm, preferably 0.1 mm to 2.0 mm, and more preferably 0.15 mm to 1.5 mm.
  • the length of the dispensing tube 94 is not particularly limited, but is preferably within 5 times the balloon diameter, for example, 1.0 mm to 50 mm, preferably 3 mm to 40 mm, more preferably 5 mm to 35 mm. .
  • the current supply unit 110 is a part that applies current to the metal layer 37 on the surface of the balloon 30.
  • the metal layer 37 generates heat when an electric current flows, and volatilizes the solvent of the coating liquid 45 to be applied.
  • the current supply unit 110 includes two terminals 111 that are slidably in contact with the distal end portion and the proximal end portion of the balloon 30, and a power source 112 that supplies current to the terminal 111.
  • the terminal 111 can flow a current supplied from the power source 112 to the metal layer 37 in contact with the terminal 111.
  • the power source 112 supplies a direct current or an alternating current to the terminal 111.
  • the power source 112 can adjust the voltage, current and frequency of the current to be supplied.
  • the two terminals 111 are in contact with a position different from a range where the coating layer 40 of the metal layer 37 is formed (a range where the coating liquid 45 is applied).
  • the position where the terminal 111 contacts is, for example, the tapered portion 33 (see FIG. 2). Thereby, the formation of the coat layer 40 is not inhibited by the terminals 111.
  • the terminal 111 is preferably flexible so that the balloon 30 and the metal layer 37 are not damaged.
  • the terminal 111 has, for example, a bifurcated structure so as to contact the metal layer 37 reliably.
  • the shape of the terminal 111 will not be specifically limited if it can contact the metal layer 37 so that sliding is possible, For example, one rod shape may be sufficient.
  • the terminal 111 can effectively pass a current through the metal layer 37.
  • the structure which can be clamped like a clip may be sufficient.
  • the deposition apparatus 120 is an apparatus that forms a metal layer 37 by depositing metal on the outer surface of the balloon 30.
  • the vapor deposition apparatus 120 can use a well-known thing.
  • the vapor deposition apparatus 120 is a vacuum vapor deposition apparatus, for example.
  • the control unit 100 is configured by a computer, for example, and comprehensively controls the rotation mechanism unit 60, the movement mechanism unit 80, the coating liquid supply unit 90, and the current supply unit 110. Therefore, the control unit 100 determines the rotational speed of the balloon 30, the moving speed of the dispensing tube 94 in the axial direction relative to the balloon 30, the drug discharge speed from the dispensing tube 94, the voltage, current, and frequency of the current supply unit 110. Can be comprehensively controlled.
  • the coating liquid 45 supplied to the metal layer 37 by the dispensing tube 94 is a solution or suspension containing the constituent material of the coat layer 40, and contains a water-insoluble drug, an additive, and a solvent. After the coating liquid 45 is supplied to the metal layer 37 on the outer surface of the balloon 30, the solvent is volatilized, so that the water-insoluble drug crystal extending on the outer surface of the metal layer 37 with an independent long axis extends. A coat layer 40 having 42 is formed.
  • the viscosity of the coating liquid 45 is 0.2 to 500 cP, preferably 0.2 to 50 cP, more preferably 0.2 to 10 cP.
  • Water-insoluble drug means a drug that is insoluble or sparingly soluble in water. Specifically, the solubility in water is less than 5 mg / mL at pH 5-8. Its solubility may be less than 1 mg / mL and even less than 0.1 mg / mL. Water-insoluble drugs include fat-soluble drugs.
  • examples of some preferred water-insoluble drugs include immunosuppressants, such as cyclosporines including cyclosporine, immunoactive agents such as rapamycin, anticancer agents such as paclitaxel, antiviral or antibacterial agents, anti-neoplastic agents, Analgesics and anti-inflammatory agents, antibiotics, antiepileptics, anxiolytics, antiparalytic agents, antagonists, neuron blocking agents, anticholinergics and cholinergic agents, antimuscarinic and muscarinic agents, antiadrenergic agents, Contains antiarrhythmic, antihypertensive, hormonal and nutritional agents.
  • immunosuppressants such as cyclosporines including cyclosporine, immunoactive agents such as rapamycin, anticancer agents such as paclitaxel, antiviral or antibacterial agents, anti-neoplastic agents, Analgesics and anti-inflammatory agents, antibiotics, antiepileptics, anxiolytics, antiparalytic agents, antagonist
  • Water-insoluble drugs are preferably paclitaxel and paclitaxel derivatives, taxanes, docetaxel and rapamycin and rapamycin derivatives, such as biolimus A9, pimecrolimus, everolimus, zotarolimus, tacrolimus, fasudil and epothilone, paclitaxel and rapamycin, especially docetaxel, and evelimel.
  • rapamycin, paclitaxel, docetaxel, and everolimus include analogs and / or derivatives thereof as long as they have similar medicinal effects.
  • paclitaxel and docetaxel are in an analog relationship.
  • Rapamycin and everolimus are in a derivative relationship. Of these, paclitaxel is more preferred.
  • Additive 41 includes a water-soluble low molecular weight compound.
  • the molecular weight of the water-soluble low molecular weight compound is 50 to 2000, preferably 50 to 1000, more preferably 50 to 500, and further preferably 50 to 200.
  • the water-soluble low molecular weight compound is preferably 5 to 10,000 parts by weight, more preferably 5 to 200 parts by weight, and still more preferably 8 to 150 parts by weight with respect to 100 parts by weight of the water-insoluble drug.
  • the constituent materials of water-soluble low molecular weight compounds are serine ethyl ester, citrate ester, polysorbate, water-soluble polymer, sugar, contrast agent, amino acid ester, glycerol ester of short-chain monocarboxylic acid, pharmaceutically acceptable salt and interface An activator or the like, or a mixture of two or more of these can be used.
  • the water-soluble low molecular weight compound has a hydrophilic group and a hydrophobic group and is characterized by being dissolved in water.
  • the water-soluble low molecular weight compound is preferably non-swellable or hardly swellable.
  • the additive 41 is preferably amorphous (amorphous) on the metal layer 37.
  • the additive 41 containing a water-soluble low-molecular compound has an effect of uniformly dispersing the water-insoluble drug on the outer surface of the metal layer 37. Furthermore, since the additive 41 is easily dissolved when the balloon 30 is expanded in the blood vessel, the water-insoluble drug crystal particles on the outer surface of the metal layer 37 can be easily released, and the drug crystal particles in the blood vessel are released. It has the effect of increasing the amount of adhesion.
  • the additive 41 is preferably not a hydrogel. Since the additive 41 is a low molecular weight compound, it dissolves rapidly without swelling when in contact with an aqueous solution.
  • the additive 41 is easily dissolved when the balloon 30 is expanded in the blood vessel, the particles of the water-insoluble drug crystal 42 on the outer surface of the metal layer 37 are easily released, and the drug crystal 42 into the blood vessel. It has the effect of increasing the amount of adhesion.
  • the additive 41 is a matrix made of a contrast agent such as Ultravist (registered trademark)
  • crystal particles are embedded in the matrix, and crystals are not generated from the metal layer 37 toward the outside of the matrix.
  • the drug crystal 42 of the present embodiment can extend from the surface of the metal layer 37 to the outside of the additive 41.
  • the solvent has low volatility so that the solvent remains in the coating liquid 45 in the entire applied range until the application of the coating liquid 45 to the entire range in which the coating layer 40 of the metal layer 37 is formed is completed.
  • the solvent contains at least one of an organic solvent and water.
  • the organic solvent is not particularly limited, and tetrahydrofuran, acetone, glycerin, acetic acid, benzene, chlorohexane, o-dichlorobenzene, o-xylene, p-xylene, cyclohexanol, styrene, cyclohexane, ethanol, methanol, dichloromethane, hexane, Examples thereof include ethyl acetate, i-butyl alcohol, s-butyl alcohol, t-butyl alcohol, propanol, butanol, toluene, and ethylene glycol. Among these, some of these mixed solvents are preferable among tetrahydrofuran, ethanol, and acetone.
  • organic solvent and water mixture examples include, for example, tetrahydrofuran and water, tetrahydrofuran and ethanol and water, tetrahydrofuran and acetone and water, acetone and ethanol and water, and tetrahydrofuran, acetone, ethanol, and water.
  • Low volatile solvents include, for example, water, acetic acid, benzene, chlorohexane, glycerin, ethanol, hexane, ethyl acetate, o-dichlorobenzene, o-xylene, p-xylene, cyclohexanol, styrene, cyclohexane, i-butyl alcohol , S-butyl alcohol, t-butyl alcohol, propanol, butanol, toluene, ethylene glycol and the like.
  • the volatility of the solvent can be adjusted by, for example, the viscosity of the solution, the concentration of the solution (solvent content ratio), and the like.
  • a metal layer 37 is formed on the outer surface of the balloon 30 by a known vapor deposition device 120. Note that the metal layer 37 can be formed only on the surface of the balloon 30 by performing masking or the like on the portion of the balloon catheter 10 where the metal layer 37 is not formed.
  • an expansion fluid is supplied into the balloon 30 through a three-way cock connected to the proximal end opening 27 of the balloon catheter 10.
  • the three-way cock is operated in a state where the balloon 30 is expanded to seal the expansion lumen 23, and the state where the balloon 30 is expanded is maintained.
  • the balloon 30 is expanded at a pressure (for example, 4 atmospheres) lower than a pressure (for example, 8 atmospheres) at the time of use in the blood vessel.
  • the coating layer 40 can also be formed on the outer surface of the balloon 30 without expanding the balloon 30, and in this case, it is not necessary to supply the expansion fluid into the balloon 30.
  • the balloon catheter 10 is rotatably installed on the support base 70, and the hub 26 is connected to the rotation mechanism 60.
  • the position of the moving table 81 is adjusted, and the dispensing tube 94 is positioned with respect to the balloon 30.
  • the dispensing tube 94 is positioned at the most distal end position where the coating layer 40 is formed in the balloon 30.
  • the extending direction (discharge direction) of the dispensing tube 94 is opposite to the rotation direction of the balloon 30 as shown in FIG. Accordingly, the balloon 30 rotates in the direction opposite to the direction in which the coating liquid 45 is discharged from the dispensing tube 94 at the position where the dispensing tube 94 is brought into contact. Thereby, physical stimulation can be given to the coating liquid 45 and formation of the crystal nucleus of a drug crystal can be promoted.
  • the extending direction (discharge direction) toward the opening 95 of the dispensing tube 94 is the direction opposite to the rotation direction of the balloon 30, so that the water-insoluble drug formed on the metal layer 37 on the surface of the balloon 30.
  • the crystal is easily formed to include a morphological form including a plurality of drug crystals 42 each having an independent major axis.
  • the extending direction of the dispensing tube 94 does not have to be the reverse direction of the rotation direction of the balloon 30, and can therefore be the same direction or can be perpendicular.
  • the balloon catheter 10 is rotated by the rotation mechanism 60. Subsequently, while the amount of liquid fed is adjusted by the liquid feed pump 93 and the coating liquid 45 is supplied to the dispensing tube 94, the moving table 81 is moved to move the dispensing tube 94 along the axial direction of the balloon 30. Gradually move toward the proximal direction.
  • the coating liquid 45 discharged from the opening 95 of the dispensing tube 94 is applied while drawing a spiral on the outer peripheral surface of the metal layer 37 as the dispensing tube 94 moves relative to the balloon 30. By rotating the balloon 30, the coating liquid 45 applied to the outer peripheral surface of the metal layer 37 tends to be uniform in the circumferential direction.
  • the moving speed of the dispensing tube 94 is not particularly limited, but is, for example, 0.01 to 2 mm / sec, preferably 0.03 to 1.5 mm / sec, and more preferably 0.05 to 1.0 mm / sec.
  • the discharge speed of the coating liquid 45 from the dispensing tube 94 is not particularly limited, but is, for example, 0.01 to 1.5 ⁇ L / sec, preferably 0.01 to 1.0 ⁇ L / sec, more preferably 0.03 to 0. .8 ⁇ L / sec.
  • the rotation speed of the balloon 30 is not particularly limited, but is, for example, 10 to 300 rpm, preferably 30 to 250 rpm, and more preferably 50 to 200 rpm.
  • the diameter of the balloon 30 when applying the coating liquid 45 is not particularly limited, but is, for example, 1 to 10 mm, preferably 2 to 7 mm.
  • the dispensing tube 94 is gradually moved in the axial direction of the balloon 30 while rotating the balloon 30.
  • the layer of the coating liquid 45 is gradually formed on the metal layer 37 on the surface of the balloon 30 in the axial direction.
  • the moving mechanism unit 80 and the coating liquid supply unit 90 are stopped. Since the solvent contained in the coating liquid 45 is low in volatility, the coating liquid 45 on the metal layer 37 is applied even after the coating liquid 45 is completely applied to the entire area where the coating layer 40 of the metal layer 37 is formed. In the entire range, the solvent remains.
  • the control unit 100 causes the power supply 112 to supply current to the terminal 111 in a state where the terminal 111 is in contact with the distal end portion and the proximal end portion of the balloon 30.
  • a current flows through the metal layer 37, the metal layer 37 generates heat, and the volatilization of the solvent of the coating liquid 45 applied to the balloon 30 is promoted.
  • the balloon 30 is rotated and the coating liquid 45 is heated in a state where the solvent of the coating liquid 45 remains in the whole range applied, so that the coating liquid 45 is kept uniform while maintaining the uniformity of the coating liquid 45.
  • the control unit 100 stops the supply of current from the power source 112 and stops the rotation of the balloon 30. Note that the supply of current from the power source 112 and the rotation of the balloon 30 may be stopped before the volatilization of the solvent is completely completed.
  • the organic solvent contained in the coating solution applied to the metal layer 37 on the outer surface of the balloon 30 is volatilized before water. Therefore, the organic solvent is volatilized in a state where the water-insoluble drug, the water-soluble low-molecular compound and water are left on the outer surface of the metal layer 37. As described above, when the organic solvent is volatilized with water remaining, a water-insoluble drug is precipitated inside the water-soluble low-molecular compound containing water, and the crystal gradually grows from the crystal nucleus.
  • a morphological drug crystal 42 containing a plurality of crystals each having an independent long axis is formed on the outer surface of the film.
  • the base of the drug crystal 42 is located on the outer surface of the metal layer 37, the surface of the additive 41, or inside the additive 41 (see FIG. 3). After the organic solvent is volatilized and the drug crystals 42 are deposited, water is evaporated more slowly than the organic solvent, and an additive 41 containing a water-soluble low-molecular compound is formed.
  • the time for which water evaporates is appropriately set according to the type of drug, the type of water-soluble low molecular weight compound, the type of organic solvent, the ratio of materials, the amount of coating solution applied, etc., for example, about 1 to 600 seconds It is.
  • the balloon catheter 10 is removed from the support base 70.
  • the expansion fluid is discharged from the balloon 30, and the balloon 30 is contracted and folded. Thereby, manufacture of the balloon catheter 10 is completed.
  • the balloon 30 has a substantially circular cross section in a state where the expansion fluid is injected therein. From this state, the balloon 30 is formed with the protruding blade portion 32, so that the blade outer portion 34a constituting the outer surface of the blade portion 32 and the inner portion of the blade portion 32 are formed as shown in FIG. A blade inner portion 34b constituting the side surface and an intermediate portion 34c located between the blade outer portion 34a and the blade inner portion 34b are formed. From this state, as shown in FIG. 7C, the blade portion 32 protruding outward in the radial direction is folded in the circumferential direction.
  • a root-side space portion 36 is formed between the root portion of the blade portion 32 and the intermediate portion 34c.
  • a minute gap is formed between the blade part 32 and the intermediate part 34c.
  • the region on the tip side of the base side space portion 36 of the blade portion 32 is in close contact with the intermediate portion 34c.
  • the ratio of the circumferential length of the base side space portion 36 to the circumferential length of the blade portion 32 is in the range of 1 to 95%.
  • the blade outer portion 34a of the balloon 30 receives a pressing force that rubs in the circumferential direction from a blade for folding the balloon 30, and is further heated. As a result, the long drug crystal 42 provided on the blade outer portion 34 a falls down on the surface of the balloon 30 and is easy to sleep. It is not necessary for all of the drug crystal 42 to sleep.
  • the drug crystal 42 is difficult to sleep.
  • the region that does not face the root side space portion 36 that is, the region where the blade inner portion 34b and the intermediate portion 34c are in close contact with each other, Easy to receive pressure. Therefore, in this region, the drug crystal 42 falls down and tends to sleep.
  • the surgeon punctures a blood vessel from the skin by a known method such as the Seldinger method, and places an introducer (not shown).
  • the guide wire 200 (see FIG. 7) is inserted into the guide wire lumen 24.
  • the guide wire 200 and the balloon catheter 10 are inserted into the blood vessel from the inside of the introducer.
  • the balloon catheter 10 is advanced while the guide wire 200 is advanced, and the balloon 30 reaches the stenosis.
  • a guiding catheter may be used to reach the balloon catheter 10 to the stenosis 300.
  • a predetermined amount of expansion fluid is injected from the proximal end opening 27 of the hub 26 using an inflator or a syringe, and the expansion fluid is sent into the balloon 30 through the expansion lumen 23.
  • the folded balloon 30 is expanded, and the narrowed portion 300 is pushed and expanded by the balloon 30.
  • the coat layer 40 provided on the reinforcing layer 35 on the surface of the balloon 30 comes into contact with the narrowed portion 300.
  • the drug crystal 42 is delivered to the living body while the additive 41, which is a water-soluble low-molecular compound contained in the coat layer 40, gradually or rapidly dissolves.
  • the drug crystals 42 of the coat layer 40 are uniformly formed by the manufacturing method described above. For this reason, a medicine can be made to act satisfactorily on a living body without variation.
  • the expansion fluid is sucked and discharged from the proximal end opening 27 of the hub 26, and the balloon 30 is deflated and folded.
  • the guide wire 200 and the balloon catheter 10 are removed from the blood vessel via the introducer, and the procedure is completed.
  • the method for manufacturing the balloon catheter 10 is a method for manufacturing the balloon catheter 10 in which the coat layer 40 containing water-insoluble drug crystals is formed on the outer surface of the balloon 30.
  • Forming a metal layer 37 by depositing a conductive metal on the outer surface of the substrate, applying a coating liquid 45 containing a drug and a solvent to the outer surface of the metal layer 37, and forming a coat layer 40 of the balloon 30
  • a current is passed through the metal layer 37 to generate heat and volatilize the solvent.
  • the solvent of the coating liquid 45 is volatilized by heating with the metal layer 37 in a state where the solvent of the coating liquid 45 remains in the entire range applied.
  • the crystallization of the entire range of drugs can be promoted simultaneously under substantially the same conditions. For this reason, the drug crystal 42 can be uniformly formed on the outer surface of the balloon 30 and the morphological form of the drug can be easily controlled regardless of various conditions and fluctuations in the procedure.
  • an electric current is supplied to the metal layer 37 by the terminal 111 that slidably contacts the metal layer 37 while rotating the balloon 30 around the axis of the balloon 30.
  • an electric current can be sent through the metal layer 37 to volatilize the solvent without stopping the rotation of the balloon 30 that plays the role of making the coating liquid 45 uniform.
  • the drug crystal 42 can be formed uniformly, and the control of the morphological type of the drug is facilitated.
  • Solvents are water, acetic acid, benzene, chlorohexane, glycerin, ethanol, hexane, ethyl acetate, o-dichlorobenzene, o-xylene, p-xylene, cyclohexanol, styrene, cyclohexane, i-butyl alcohol, s- It may be at least one selected from the group consisting of butyl alcohol, t-butyl alcohol, propanol, butanol, toluene, and ethylene glycol. Thereby, the volatility of the solvent is lowered, and the solvent is less likely to volatilize from the coating liquid 45 applied to the balloon 30.
  • the water-insoluble drug may contain at least one selected from the group consisting of rapamycin, paclitaxel, docetaxel and everolimus.
  • the manufacturing apparatus 50 for the balloon catheter 10 applies a drug and a solvent to the outer surface of the rotation mechanism 60 that applies a rotational force to the balloon 30 and the metal layer 37 deposited on the rotating balloon 30.
  • the coating liquid supply part 90 which apply
  • the manufacturing apparatus 50 configured as described above supplies a current to the metal layer 37 by the terminal 111 slidably contacting the metal layer 37 of the rotating balloon 30 in a state where the solvent of the coating liquid 45 remains.
  • the metal layer 37 can generate heat, and the solvent of the coating liquid 45 can be volatilized.
  • crystallization of the whole range of the applied drug can be promoted simultaneously under substantially the same conditions. Therefore, the drug crystal 42 can be uniformly formed on the outer surface of the balloon 30 regardless of various conditions and the fluctuation of the technique, and the morphological type of the drug can be easily controlled.
  • the balloon catheter 10 is a balloon catheter 10 that can be inserted into a living body lumen, and is provided on the distal side of the long catheter body 20 and the catheter body 20 so as to expand in the radial direction.
  • the drug crystal 42 is disposed on the outer surface of the metal layer 37, the transfer property of the drug to the living body is adjusted by the metal layer 37 having a surface structure different from that of the balloon 30. it can.
  • the present invention also includes a treatment method (therapeutic method) for delivering a drug to a lesion in a living body lumen using the balloon catheter 10.
  • the treatment method includes a step of inserting the balloon 30 into the body lumen to reach the lesioned part, a step of expanding the balloon 30 and the metal layer 37 and pressing the body 30 against the living tissue, and bringing the drug crystal 42 into contact with the living tissue. And deflating the balloon 30 to remove it from the living body lumen.
  • the metal layer 37 having a surface structure different from that of the balloon 30 is used. Transferability to living tissue can be adjusted.
  • the balloon catheter 10 according to the above-described embodiment is a rapid exchange type, but may be an over-the-wire type.
  • the balloon catheter 10 may move along the axis without moving the dispensing tube 94.
  • the balloon catheter 10 further includes a conductive wire 39 that is electrically connected to the metal layer 37 and extends proximally along the catheter body 20. May be.
  • the conducting wire 39 can be connected to an external power supply device (not shown) via 28 provided on the hub 26. Thereby, an electric current can be supplied to the metal layer 37 disposed on the balloon 30 inserted in the living body via the conductive wire 39. For this reason, the drug crystal 42 can be heated by the metal layer 37 in the living body to improve the transferability of the drug to the living tissue.
  • the metal layer 37 may be partially provided on the outer surface of the balloon 30.
  • a part of the balloon 30 has an exposed portion 38 where the metal layer 37 is not provided.
  • the exposed portion 38 can be formed by masking the surface of the balloon 38 when the metal layer 37 is deposited on the balloon 30.
  • the coat layer 40 is directly disposed on the exposed portion 38 of the balloon 30.
  • the shape of the exposed portion 38 is not particularly limited.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne : un cathéter à ballonnet capable de former uniformément un cristal de médicament sur la surface extérieure d'un ballonnet et capable de contrôler facilement la forme morphologique du médicament; un procédé de production associé; un dispositif de production; et un procédé de traitement. Ce procédé de production d'un cathéter à ballonnet (10) ayant une couche de revêtement (40) comprenant des cristaux d'un médicament insoluble dans l'eau, formée sur la surface externe d'un ballonnet (30), comprend : une étape dans laquelle un métal conducteur est déposé et une couche métallique (37) est formée sur la surface externe du ballonnet (30); une étape dans laquelle un fluide de revêtement (45) comprenant le médicament et un solvant est appliqué sur la surface externe de la couche métallique (37); et une étape dans laquelle, après le revêtement du fluide de revêtement (45) sur toute la surface formant la couche de revêtement (40) du ballonnet (30) a été achevé, du courant est fourni à la couche métallique (37), de la chaleur est générée, et le solvant est volatilisé, dans un état dans lequel le solvant de fluide de revêtement (45) reste.
PCT/JP2018/010472 2017-03-16 2018-03-16 Cathéter à ballonnet, son procédé de production, dispositif de production, et procédé de traitement WO2018169053A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019506299A JP7073338B2 (ja) 2017-03-16 2018-03-16 バルーンカテーテルおよびその製造方法および製造装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017050838 2017-03-16
JP2017-050838 2017-03-16

Publications (1)

Publication Number Publication Date
WO2018169053A1 true WO2018169053A1 (fr) 2018-09-20

Family

ID=63523575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/010472 WO2018169053A1 (fr) 2017-03-16 2018-03-16 Cathéter à ballonnet, son procédé de production, dispositif de production, et procédé de traitement

Country Status (2)

Country Link
JP (1) JP7073338B2 (fr)
WO (1) WO2018169053A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002113092A (ja) * 2000-08-04 2002-04-16 Japan Lifeline Co Ltd 医療用具の製造方法および医療用具
JP2007144170A (ja) * 2005-11-23 2007-06-14 Cordis Corp 脈管の傷害後の再狭窄を防ぐための、ｐｉ３キナーゼ抑制因子の、単独の、あるいは、シロリムスとの組み合わせにおける、局所脈管送達
JP2007534362A (ja) * 2003-12-16 2007-11-29 クック インコーポレイテッド 永久的に取付けられた導体を備えているステントカテーテル
JP2009531157A (ja) * 2006-03-24 2009-09-03 ボストン サイエンティフィック リミテッド 電気的に作動可能な表面を有する方法および機器
JP2011517589A (ja) * 2008-03-28 2011-06-16 サーモディクス，インコーポレイティド 微粒子が配置された弾性基質を有する挿入可能な医療機器、および薬物送達方法
JP2015516237A (ja) * 2012-05-09 2015-06-11 クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＣｏｏｋ Ｍｅｄｉｃａｌ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｌｃ 水不溶性治療剤と添加剤とを含むコーティングがなされた医療装置
WO2015151877A1 (fr) * 2014-04-01 2015-10-08 テルモ株式会社 Procédé de revêtement de ballonnet, procédé de commande de couche de revêtement et dispositif de revêtement de ballonnet
JP2016202916A (ja) * 2015-04-23 2016-12-08 テルモ株式会社 バルーンコーティング方法、バルーン回転方法およびバルーンコーティング装置

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002113092A (ja) * 2000-08-04 2002-04-16 Japan Lifeline Co Ltd 医療用具の製造方法および医療用具
JP2007534362A (ja) * 2003-12-16 2007-11-29 クック インコーポレイテッド 永久的に取付けられた導体を備えているステントカテーテル
JP2007144170A (ja) * 2005-11-23 2007-06-14 Cordis Corp 脈管の傷害後の再狭窄を防ぐための、ｐｉ３キナーゼ抑制因子の、単独の、あるいは、シロリムスとの組み合わせにおける、局所脈管送達
JP2009531157A (ja) * 2006-03-24 2009-09-03 ボストン サイエンティフィック リミテッド 電気的に作動可能な表面を有する方法および機器
JP2011517589A (ja) * 2008-03-28 2011-06-16 サーモディクス，インコーポレイティド 微粒子が配置された弾性基質を有する挿入可能な医療機器、および薬物送達方法
JP2015516237A (ja) * 2012-05-09 2015-06-11 クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＣｏｏｋ Ｍｅｄｉｃａｌ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｌｃ 水不溶性治療剤と添加剤とを含むコーティングがなされた医療装置
WO2015151877A1 (fr) * 2014-04-01 2015-10-08 テルモ株式会社 Procédé de revêtement de ballonnet, procédé de commande de couche de revêtement et dispositif de revêtement de ballonnet
JP2016202916A (ja) * 2015-04-23 2016-12-08 テルモ株式会社 バルーンコーティング方法、バルーン回転方法およびバルーンコーティング装置

Also Published As

Publication number Publication date
JP7073338B2 (ja) 2022-05-23
JPWO2018169053A1 (ja) 2020-04-09

Similar Documents

Publication Publication Date Title
WO2015151876A1 (fr) Procédé de revêtement de ballonnet
WO2015151877A1 (fr) Procédé de revêtement de ballonnet, procédé de commande de couche de revêtement et dispositif de revêtement de ballonnet
JP6472572B2 (ja) バルーンカテーテルおよびその製造方法並びに処置方法
JP6498664B2 (ja) バルーンコーティングのための位置決め方法およびバルーンコーティング方法
WO2015151878A1 (fr) Procédé de positionnement pour revêtement de ballonnet
JP2018153288A (ja) バルーンカテーテルの製造方法および製造装置
WO2017164280A1 (fr) Cathéter à ballonnet, procédé de production de cathéter à ballonnet, et procédé de traitement
JP2018153283A (ja) バルーンコーティング方法
JP2017169740A (ja) バルーンカテーテルおよびその製造方法並びに処置方法
JP6668131B2 (ja) バルーンカテーテルおよびその製造方法並びに処置方法
WO2018169052A1 (fr) Méthode de production de cathéter à ballonnet
JP6831722B2 (ja) バルーンカテーテルの製造方法および製造装置
JP2018153291A (ja) バルーンカテーテルの製造方法および製造装置
WO2018169054A1 (fr) Cathéter à ballonnet, son procédé de production et procédé de traitement
JP2017169738A (ja) バルーンカテーテルおよびその製造方法並びに処置方法
WO2018169053A1 (fr) Cathéter à ballonnet, son procédé de production, dispositif de production, et procédé de traitement
WO2018169051A1 (fr) Procédé de revêtement de ballonnet
JP2017169734A (ja) バルーンカテーテル及びその製造方法並びに処置方法
JP2017169741A (ja) バルーンカテーテルおよび処置方法
JP2017169737A (ja) バルーンカテーテル及びその製造方法並びに処置方法
JP2018153289A (ja) バルーンカテーテルの製造方法および製造装置
JP2015195961A (ja) バルーンコーティング方法およびバルーンコーティング装置
JP2018153286A (ja) バルーンコーティング方法
JP2017169733A (ja) バルーンカテーテルおよびその製造方法並びに処置方法
JP2017169735A (ja) バルーンカテーテル及びその製造方法並びに処置方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18768715

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019506299

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18768715

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载